Biogen (BIIB)
Salud / Farmacéutica
Biogen trades near its 52-week high while it repositions its portfolio: the legacy multiple sclerosis franchise keeps eroding from generics and biosimilars, but the Growth Portfolio (SKYCLARYS, QALSODY, ZURZUVAE, LEQEMBI, and now SYFOVRE/EMPAVELI after the Apellis acquisition) already exceeds the legacy portfolio in revenue and grows 24% year over year. The Preserves value reflects a business in transition, with GAAP earnings still depressed by non-recurring integration charges.
- Price
- $221.85
- Intrinsic value (5y, base)
- $253
- Total annual return (5y)
- 2.7%
- Status (nominal)
- Preserves value
- Margin of safety
- No margin
The essentials
- The Growth Portfolio (SKYCLARYS, QALSODY, ZURZUVAE, SPINRAZA, SYFOVRE, EMPAVELI, LEQEMBI) generated more revenue than the legacy multiple sclerosis portfolio for the first time in the second quarter of 2026, growing 24% year over year.
- TTM GAAP earnings are heavily depressed by non-recurring Apellis integration, litigation and restructuring charges; normalized adjusted earnings are several times higher.
- The legacy multiple sclerosis franchise (TECFIDERA, TYSABRI) remains relevant to total revenue but faces active erosion from generics and a TYSABRI biosimilar.
- The company does not pay a dividend and paused share buybacks since 2023 to fund M&A (Apellis, pending RayThera).
Intrinsic value — two valuation methods
The methods disagree: one places the value today above the price ($222) and the other below.
Pillars of the analysis
The verdict — today vs 5 years
Today — expensive, no margin of safety: at $222 trades ~8.8% above its value discounted to today (~$204); the expected return does not even reach the risk-free rate (4.5%).
At 5 years — Preserva valor: the target price ($254) plus dividends yield just enough to preserve nominal capital, below the required 4% floor.
The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$126.
Thesis
The business
A biopharmaceutical company in structural transition: a legacy multiple sclerosis franchise declining from generics and biosimilars, offset by a Growth Portfolio of rare disease and specialty immunology that already exceeds the legacy portfolio in revenue and grows 24% year over year, reinforced by the Apellis acquisition (closed May 2026).
The valuation
Valued on a P/E basis over normalized adjusted earnings (multiple 22×), excluding non-recurring Apellis integration, litigation and restructuring charges. The 5-year value implies +3% of annual growth relative to the market price, with the base-case exit multiple at the floor of the pharma band due to the eroding direction of the legacy moat.
The margin of safety
No margin of safety: at this price capital is preserved, but it is not bought below its value. The stock trades at only 3% below its 52-week high, so the market already recognizes much of the Growth Portfolio's strength; the margin of safety depends on the post-Apellis-integration margin normalization materializing as guided.
What to watch
The key test is whether the Growth Portfolio sustains its double-digit growth long enough to offset the decline of the legacy franchise before it erodes completely, and whether the Apellis integration delivers the at-least-US$250-million annual synergies guided for the end of 2027 without further execution surprises. Added to that is a legal front to monitor: the appeal of the Genentech judgment, the contested German tax assessment, and the antitrust litigation over the TECFIDERA and VUMERITY contracts, none of which is reserved on the balance sheet.
Educational / informational. Does not constitute investment advice.